We are adding the following positions for the May portfolio.
We are recommending credit spreads in the following issues.
AMGN - Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and delivers human therapeutics based on advances in cellular and molecular biology primarily in the United States, Europe, and Canada. The company markets primarily recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases.
SBUX - Starbucks Corporation engages in the purchase, roasting, and sale of whole bean coffees worldwide. It offers brewed coffees, Italian-style espresso beverages, cold blended beverages, various complementary food items, and a selection of premium teas, as well as beverage-related accessories and equipment, through its retail stores. The company also licenses its trademark through other channels, such as licensed retail stores, as well as through certain of its licensees and equity investees.
AMAG - AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic iron compounds to treat iron deficiency anemia (IDA) in the United States, Europe, and Japan. It also provides novel imaging agents to aid in the diagnosis of cancer and cardiovascular diseases. It offers Feraheme, an iron replacement therapeutic for the treatment of IDA in adult patients with chronic kidney disease; and GastroMARK used for delineating the bowel in magnetic resonance imaging (MRI). The company is also developing Feraheme, which is in Phase II clinical trials for use as a vascular-enhanced MRI agent for the assessment of peripheral arterial disease.
MOS - The Mosaic Company engages in the production and marketing of concentrated phosphate and potash crop nutrients for the agriculture industry worldwide. The company produces phosphate crop nutrients for use in crop nutrients and feed phosphate for animal feed ingredients. It also produces and sells potash for use as fertilizers and animal feed ingredients, as well as in industrial applications. Potash is also used for de-icing and as a water softener regenerant. In addition, The Mosaic Company produces and/or markets phosphate-, potash-, and nitrogen-based crop nutrients and animal feed ingredients, as well as operates sales offices, crop nutrient blending and bagging facilities, port terminals, and warehouses.
MEE - Massey Energy Company , through its wholly owned subsidiary, A.T. Massey Coal Company, Inc., produces, processes, and sells bituminous coal primarily in the United States. As of January 31, 2010, it operated 56 mines, including 42 underground mines and 14 surface mines in West Virginia, Kentucky, and Virginia. The company also owns and operates approximately 160 wells, 200 miles of gathering line, and various small compression facilities in Appalachian Basin. Massey Energy Company?s customers include electric utilities, steel manufacturers, industrial customers, and energy traders and brokers. It distributes its products through freight and terminal agreements with various providers, including railroads, barge lines, ocean-going vessels, bulk motor carriers, and terminal facilities.
We are recommending the following specific credit spreads.
Call credit spreads = bearish credit spreads.
Supplemental ETF/INDEX/Holder play.
The following issue is a candidate to supplement
your search for profitable EFT and Index trades. As with any investment, you
must decide if the selection meets your criteria for a potential play.
Only you can know what strategies and positions are suitable for your
experience level, risk-reward tolerance and individual outlook.
There will be no commentary or analysis offered on this position
nor will it be included in the MCM Portfolio.